Difference between revisions of "Medical Reporting/Vaccine and Treatment News"
Jump to navigation
Jump to search
| Line 14: | Line 14: | ||
==Peer-Reviewed Research== | ==Peer-Reviewed Research== | ||
* SEP 2015 [https://pubmed.ncbi.nlm.nih.gov/26133021/ Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection] | * SEP 2015 [https://pubmed.ncbi.nlm.nih.gov/26133021/ Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection] | ||
| + | * 24 MAR 2020 [https://www.fda.gov/emergency-preparedness-and-response/mcm-regulatory-science/investigating-decontamination-and-reuse-respirators-public-health-emergencies Investigating Decontamination and Reuse of Respirators in Public Health Emergencies] | ||
Revision as of 08:36, 31 March 2020
Contents
Medical Reporting and Research
Minimal Requirement of being a verified major news outlet with a high unbiased rating on The Media Bias Chart and/or from reputable sources, such as research facilities and universities
Strong recommendation to not take action or make assumptions based upon research which may be dated, changing or part of ongoing research
Published for General Public Reading
- 8 strains of the coronavirus are circling the globe. Here's what clues they're giving scientists.
- Conclusions: Our findings suggest that patients with a shorter incubation period went on to have more severe disease. Further studies are needed to investigate potential biological mechanisms for this association.
- 27 MAR 2020 How sick will the coronavirus make you? The answer may be in your genes
- 25 MAR 2020 Sweden bucks global trend with experimental virus strategy
- 24 MAR 2020 Mount Sinai to Begin the Transfer of COVID-19 Antibodies into Critically Ill Patients - The Mount Sinai Health System this week plans to initiate a procedure known as plasmapheresis, where the antibodies from patients who have recovered from COVID-19 will be transferred into critically ill patients with the disease, with the expectation that the antibodies will neutralize it.
